Literature DB >> 15829322

Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer.

Nanna Junker1, Julia S Johansen, Claus B Andersen, Paul E G Kristjansen.   

Abstract

YKL-40 is a 40 kDa protein with possible involvement in tissue remodeling, cell proliferation and angiogenesis. Elevated serum YKL-40 levels in patients with metastatic cancers (including small cell lung cancer (SCLC)) are associated with poor prognosis. The aim of this study was to identify the cellular source of YKL-40 in SCLC patient biopsies and in a panel of 20 human SCLC lines cultured in vitro and in vivo in nude mice. In general, the SCLC cell lines had no or very limited (human) YKL-40 expression, whereas, by RT-PCR a pronounced murine (i.e., stromal) YKL-40 expression was present in all tumors. YKL-40 mRNA transcripts were detected by in situ hybridization in 9 of 10 biopsies from SCLC patients, and in each case the signal was localized in the peritumoral stroma in cells of typical macrophage morphology (confirmed by a CD68 macrophage specific stain). No YKL-40 mRNA expression was found in the cancer cells, in macrophages infiltrating the solid tumor areas, or in non-malignant tissue. In conclusion, the predominant source of elevated serum YKL-40 in SCLC is peritumoral macrophages.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15829322     DOI: 10.1016/j.lungcan.2004.11.011

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  43 in total

1.  Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation.

Authors:  Dafna Bonneh-Barkay; Stephanie J Bissel; Julia Kofler; Adam Starkey; Guoji Wang; Clayton A Wiley
Journal:  Brain Pathol       Date:  2011-12-22       Impact factor: 6.508

2.  Clinical correlation between serum YKL-40 protein level and recurrence of non-muscle invasive bladder cancer.

Authors:  Jiasheng Yan; Peijun Shen; Junhua Zheng; Min Liu
Journal:  Ann Transl Med       Date:  2015-12

Review 3.  New Insights Into the Relationship Between Chitinase-3-Like-1 and Asthma.

Authors:  Daniel Elieh Ali Komi; Tohid Kazemi; Anton Pieter Bussink
Journal:  Curr Allergy Asthma Rep       Date:  2016-08       Impact factor: 4.806

4.  Potential suppressive effects of theophylline on human rectal cancer SW480 cells in vitro by inhibiting YKL-40 expression.

Authors:  Hong Peng; Qiang Su; Zhong-Chao Lin; Xiu-Hua Zhu; Ming-Sha Peng; Zhen-Bing Lv
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

5.  Chitinase-like proteins in lung injury, repair, and metastasis.

Authors:  Chun Geun Lee; Charles S Dela Cruz; Bing Ma; Farida Ahangari; Yang Zhou; Ruth Halaban; Mario Sznol; Jack A Elias
Journal:  Proc Am Thorac Soc       Date:  2012-05

6.  Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation.

Authors:  Kristoffer Mads Henningsen; Brian Nilsson; Julia S Johansen; Xu Chen; Steen Pehrson; Jesper Hastrup Svendsen
Journal:  Inflamm Res       Date:  2009-12-10       Impact factor: 4.575

Review 7.  Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells.

Authors:  Katrin Eurich; Mayuko Segawa; Satoko Toei-Shimizu; Emiko Mizoguchi
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

Review 8.  Circulating tumor cell interactions with macrophages: implications for biology and treatment.

Authors:  Gerhard Hamilton; Barbara Rath
Journal:  Transl Lung Cancer Res       Date:  2017-08

Review 9.  Smoking, inflammation and small cell lung cancer: recent developments.

Authors:  Gerhard Hamilton; Barbara Rath
Journal:  Wien Med Wochenschr       Date:  2015-08-20

10.  YKL-40 tissue expression and plasma levels in patients with ovarian cancer.

Authors:  Estrid V S Høgdall; Merete Ringsholt; Claus K Høgdall; Ib Jarle Christensen; Julia S Johansen; Susanne K Kjaer; Jan Blaakaer; Lene Ostenfeld-Møller; Paul A Price; Lise H Christensen
Journal:  BMC Cancer       Date:  2009-01-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.